Inamed Finalizing Lap-Band Treatment IDE Plans, Collecting Three-Year Data
This article was originally published in The Gray Sheet
Executive Summary
Inamed is expecting to hear from FDA within the next few weeks about expanding its Lap-Band obesity treatment training program under a treatment investigational device exemption, President and co-CEO Ilan Reich told a July 25 teleconference announcing second-quarter financial results.
You may also be interested in...
Inamed
McGhan Medical subsidiary's round saline breast implants used for augmentation will cost 12% more as of Sept. 15, parent company Inamed says in an Aug. 7 release. The price hike is the first in five years and may affect third quarter financials depending on the reaction of customers and competitors, according to company President and CEO Ilan Reich. Recent speculation over breast implant price erosion has raised concern on Wall Street (1"The Gray Sheet" July 31, p. 7)
Inamed
McGhan Medical subsidiary's round saline breast implants used for augmentation will cost 12% more as of Sept. 15, parent company Inamed says in an Aug. 7 release. The price hike is the first in five years and may affect third quarter financials depending on the reaction of customers and competitors, according to company President and CEO Ilan Reich. Recent speculation over breast implant price erosion has raised concern on Wall Street (1"The Gray Sheet" July 31, p. 7)
Inamed's Two-Year Data Insufficient For Lap-Band Approval - Panel
Inamed will be able to provide FDA with three-year follow-up data in the third quarter on roughly 150 patients implanted with the firm's Lap-Band adjustable gastric banding system for obesity treatment, according to company officials.